Literature DB >> 18282015

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Sun-Young Kim1, Sue J Goldie.   

Abstract

Cost effectiveness is becoming an increasingly important factor for stakeholders faced with decisions about adding a new vaccine into national immunization programmes versus alternative use of resources. Evaluating cost effectiveness, taking into account the relevant biological, clinical, epidemiological and economic factors of a vaccination programme, generally requires use of a model. This review examines the modelling approaches used in cost-effectiveness analyses (CEAs) of vaccination programmes.After overviewing the key attributes of models used in CEAs, a framework for categorising theoretical models is presented. Categories are based on three main attributes: static/dynamic; stochastic/deterministic; and aggregate/individual based. This framework was applied to a systematic review of CEAs of all currently available vaccines for the period of 1976 to May 2007. The systematic review identified 276 CEAs of vaccination programmes. The great majority (83%) of CEAs were conducted in the setting of high-income countries. Only a few vaccines were widely studied, with 57% of available CEAs being focused on the varicella, influenza, hepatitis A, hepatitis B or pneumococcal vaccine. Several time trends were evident, indicating that the number of vaccine CEAs being published is increasing; the main health outcome measures are moving away from the number of cases prevented towards quality-adjusted and unadjusted life-years gained, and more complex models are beginning to be used. The modelling approach was often not adequately described. Of the 208 CEAs that could be categorized according to the framework, around 90% were deterministic, aggregate-level static models. Although a dynamic transmission model is required to account for herd-immunity effects, only 23 of the CEAs were dynamic. None of the CEAs were individual based. To improve communication about the cost effectiveness of vaccination programmes, we believe the first step is for analysts to be more transparent with each other. A clear description of the model type using consistent terminology and justification for the model choice must begin to accompany all CEAs. As a minimum, we urge modellers to provide an explicit statement about the following attributes: static/dynamic; stochastic/deterministic; aggregate/individual based; open/closed. Where relevant, time intervals (discrete/continuous) and (non)linearity should also be described. Enhanced methods of assessing model performance and validity are also required. Our results emphasize the need to improve modelling methods for CEAs of vaccination programmes; specifically, model choice, construction, assessment and validation.

Entities:  

Mesh:

Year:  2008        PMID: 18282015     DOI: 10.2165/00019053-200826030-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  97 in total

1.  Stochastic league tables: communicating cost-effectiveness results to decision-makers.

Authors:  R C Hutubessy; R M Baltussen; D B Evans; J J Barendregt; C J Murray
Journal:  Health Econ       Date:  2001-07       Impact factor: 3.046

2.  Validation of health economic models: the example of EVITA.

Authors:  Thomas Hammerschmidt; Anita Goertz; Stefan Wagenpfeil; Albrecht Neiss; Peter Wutzler; Kurt Banz
Journal:  Value Health       Date:  2003 Sep-Oct       Impact factor: 5.725

3.  Cost-effectiveness analysis: can we reduce variability in costing methods?

Authors:  Taghreed Adam; Marc A Koopmanschap; David B Evans
Journal:  Int J Technol Assess Health Care       Date:  2003       Impact factor: 2.188

4.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.

Authors:  Jonathan Karnon
Journal:  Health Econ       Date:  2003-10       Impact factor: 3.046

5.  Accounting for future costs in medical cost-effectiveness analysis.

Authors:  D Meltzer
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

6.  A guide to cost-effectiveness acceptability curves.

Authors:  Elisabeth Fenwick; Sarah Byford
Journal:  Br J Psychiatry       Date:  2005-08       Impact factor: 9.319

7.  Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.

Authors:  M Brisson; W J Edmunds
Journal:  Med Decis Making       Date:  2006 Sep-Oct       Impact factor: 2.583

Review 8.  Economic evaluations of pneumococcal vaccination strategies in adults. A summary of the results.

Authors:  N Thiry; P Beutels; P Van Damme
Journal:  Acta Clin Belg       Date:  2005 Nov-Dec       Impact factor: 1.264

Review 9.  Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.

Authors:  Mark A Miller; Cathryn K Shahab
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  Programme costs in the economic evaluation of health interventions.

Authors:  Benjamin Johns; Rob Baltussen; Raymond Hutubessy
Journal:  Cost Eff Resour Alloc       Date:  2003-02-26
View more
  57 in total

1.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

Review 2.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 3.  Economic evaluations of childhood influenza vaccination: a critical review.

Authors:  Anthony T Newall; Mark Jit; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

Review 4.  Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?

Authors:  Livio Garattini; Anna Padula; Milene Rangel Da Costa
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

5.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

Review 6.  Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources.

Authors:  Joke Bilcke; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines.

Authors:  Livio Garattini; Katelijne Van de Vooren; Nick Freemantle
Journal:  J R Soc Med       Date:  2014-01       Impact factor: 5.344

Review 8.  A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus.

Authors:  Yiling Jiang; Aline Gauthier; Maarten J Postma; Laureen Ribassin-Majed; Nathalie Largeron; Xavier Bresse
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

Review 9.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

10.  Health and economic impact of rotavirus vaccination in GAVI-eligible countries.

Authors:  Sun-Young Kim; Steve Sweet; David Slichter; Sue J Goldie
Journal:  BMC Public Health       Date:  2010-05-14       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.